Professional Documents
Culture Documents
Nombre/Descripcin Diseo y construccin de una planta para la produccin de principios activos biotecnolgicos
Disear y construir una planta para la produccin de diversos principios activos biotecnolgicos, que le permitira a PiSA contar con un
Objetivo eficacia que cumpla con la regulacin nacional e internacional (FDA y EMMEA), permitiendo as aumentar la cantidad de medicamento
iniciar una independencia de la adquisicin de los principios activos biotecnolgicos con los proveedores externos.
Apoyo a : Apoyo a :
** Clientes Mdicos
Cdula
Evento: Proyectos: X
Asignacin de Gastos
Centro de Costos
30100000
Gastos a Realizar
CONCEPTO
Err:509
Err:509
OBRA CVIL
Err:509
Err:509
Err:509
Err:509
Servicios Crticos
Err:509
Err:509
Pg.. 1/65
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Servicios de Planta
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Pg.. 2/65
Activo fijo Err:509
Err:509
Pg.. 3/65
Activo fijo Err:509
Pg.. 4/65
Activo fijo Err:509
Err:509
Pg.. 5/65
Escala piloto (Purificacin)
Pg.. 6/65
Activo fijo Err:509
Laboratorio de Calidad
Pg.. 7/65
Activo fijo Err:509
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Pg.. 8/65
Costo de Importacin
Cmaras fras
Equipo de Lavado
Integracin de Equipos
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
TOTAL
Presupuesto Autorizado por la cantidad de:
Tipo de Moneda
Presupuesto Original
Total suplemento
Pg.. 9/65
Firmas de Autorizacin
** Los apoyos a clientes debern anexar informe de rentabilidad del cliente proporcionado por Control Financiero
El original se conserva durante 2 aos en el departamento de Control Financiero
Pg.. 10/65
6-Mar-15
ALTA x
RECLASIFICACIN
e principios activos biotecnolgicos
ecnolgicos, que le permitira a PiSA contar con una instalacin para la produccin de biofrmacos de alta calidad, seguridad y
rmitiendo as aumentar la cantidad de medicamentos biotecnolgicos, disminuir los costos de manufactura de los mismos e
s con los proveedores externos.
2017/02/01
aaaa/mm/dd
Apoyo a : Apoyo a :
Hospitales Asociaciones
que no son clientes
Otros:
Responsable
MC. Marleby Garca Gonzlez
Importe
CEPTO
Err:509
$ 6,817,638.00
Err:509
Err:509
Err:509
Err:509
Err:509
Pg.. 11/65
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 12/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 13/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 14/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 15/65
in)
de encapsulado) Err:509
de filtracin Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Industrial Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
eactor Err:509
:509 Err:509
:509 Err:509
:509 Err:509
nador Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
oto
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 16/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Piloto
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
r de Inoculo Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Desmineralizante Err:509
:509 Err:509
:509 Err:509
:509 Err:509
ad
Pg.. 17/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
0 Err:509
0 Err:509
:509 Err:509
0 Err:509
0 Err:509
0 Err:509
0 Err:509
0 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
0 Err:509
0 Err:509
:509 Err:509
0 Err:509
:509 Err:509
:509 Err:509
0 Err:509
0 Err:509
0 Err:509
Pg.. 18/65
n
:509 Err:509
etador Err:509
:509 Err:509
:509 Err:509
Err:509
os
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
USD
Err:509
1.09 USD/EURO
Err:509
$ -
Err:509
Pg.. 19/65
de Autorizacin
Firma Firma
Nivel 4 Nivel 5
Nombre: Santiago lvarez / Juan Carlos
Nombre: Carlos lvarez
lvarez
ntrol Financiero
Pg.. 20/65
AFIOIN-F01-I01 Versin 7 FECHA DE ELABORACIN 6-Mar-15
Formato Orden Interna
Cdigo
Nombre/Descripcin Diseo y construccin de una planta para la produccin de principios activos biotecnolgicos
Disear y construir una planta para la produccin de diversos principios activos biotecnolgicos, que le permitira a PiSA contar con un
Objetivo eficacia que cumpla con la regulacin nacional e internacional (FDA y EMMEA), permitiendo as aumentar la cantidad de medicamento
iniciar una independencia de la adquisicin de los principios activos biotecnolgicos con los proveedores externos.
Apoyo a : Apoyo a :
** Clientes Mdicos
Cdula
Evento: Proyectos: X
Asignacin de Gastos
Centro de Costos
30100000
Gastos a Realizar
CONCEPTO
Err:509
Err:509
OBRA CVIL
Err:509
Err:509
Err:509
Err:509
Servicios Crticos
Err:509
Err:509
Pg.. 21/65
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Servicios de Planta
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Pg.. 22/65
Activo fijo Err:509
Err:509
Pg.. 23/65
Activo fijo Err:509
Pg.. 24/65
Activo fijo Err:509
Err:509
Pg.. 25/65
Escala piloto (Purificacin)
Pg.. 26/65
Activo fijo Err:509
Laboratorio de Calidad
Pg.. 27/65
Activo fijo Err:509
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Activo fijo 0
Pg.. 28/65
Costo de Importacin
Cmaras fras
Equipo de Lavado
Integracin de Equipos
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
KUBIO
Err:509
TOTAL
Presupuesto Autorizado por la cantidad de:
Tipo de Moneda
Presupuesto Original
Total suplemento
Pg.. 29/65
Total Presupuesto Evento
Firmas de Autorizacin
** Los apoyos a clientes debern anexar informe de rentabilidad del cliente proporcionado por Control Financiero
El original se conserva durante 2 aos en el departamento de Control Financiero
Pg.. 30/65
6-Mar-15
ALTA x
RECLASIFICACIN
e principios activos biotecnolgicos
ecnolgicos, que le permitira a PiSA contar con una instalacin para la produccin de biofrmacos de alta calidad, seguridad y
rmitiendo as aumentar la cantidad de medicamentos biotecnolgicos, disminuir los costos de manufactura de los mismos e
s con los proveedores externos.
2017/02/01
aaaa/mm/dd
Apoyo a : Apoyo a :
Hospitales Asociaciones
que no son clientes
Otros:
Responsable
MC. Marleby Garca Gonzlez
Importe
CEPTO
Err:509
Err:509
Pg.. 31/65
-
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 32/65
:509 Err:509
:509 -
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 -
:509 -
:509 Err:509
Pg.. 33/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 34/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 -
:509 -
Lnea de produccin -
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 35/65
in)
de encapsulado) Err:509
de filtracin Err:509
:509 Err:509
:509 -
:509 Err:509
:509 Err:509
Industrial Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
eactor Err:509
:509 Err:509
:509 Err:509
:509 Err:509
nador Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
oto
:509 Err:509
:509 Err:509
:509 Err:509
Pg.. 36/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Piloto
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
r de Inoculo Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
Desmineralizante Err:509
:509 Err:509
:509 Err:509
:509 Err:509
ad
Pg.. 37/65
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
0 Err:509
0 Err:509
:509 Err:509
0 Err:509
0 Err:509
0 Err:509
0 Err:509
0 Err:509
:509 Err:509
:509 Err:509
:509 Err:509
0 Err:509
0 Err:509
:509 Err:509
0 Err:509
:509 Err:509
:509 Err:509
0 Err:509
0 Err:509
0 Err:509
Pg.. 38/65
n
:509 Err:509
etador Err:509
:509 Err:509
:509 Err:509
Err:509
os
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
Err:509
USD
Err:509
1.09 USD/EURO
Err:509
$ -
Pg.. 39/65
Err:509
de Autorizacin
Firma Firma
Nivel 4 Nivel 5
Nombre: Santiago lvarez / Juan Carlos
Nombre: Carlos lvarez
lvarez
ntrol Financiero
Pg.. 40/65
Descripcin general
Unidad de
Equipo Marca Proveedor Cantidad
Medida
Lnea de produccin
Molinos coloidales de
Molino Industrial Coloide Latinoamrica S.A. De 1 L/h
C.V.
Refrigeracin
Enfriador de Almacen Carrier especializada de 1 Tons
Monterrey
Mezclador rotativo-MV Mezcla de productos de morfologa frgil que debe respetarse durante la mezcla N/A
230VAC / 1 Phase
380VAC/ 3 Phase
130VAC
Peso Dimensiones (cm) rea
Capacidad
Full (Kg) L (largo) W (Profundo) H (Alto) A (m2)
Profibus - DP 2 - (Wall)
Condensate, steam
Temperature Signal
CCA - 35-70 psig
TCU Connected
Cable (Ceiling)
Efficiency (%)
volume, 99C
Power supply
CO2 - 2 psi
O2 - 2 psi
50/60 Hz
N2-2 psi
Drenaje
(Lb/Hr)
Watts
GPM
UPS
1500 Suministro electrico 60 - - - - - x - - - - - - - -
- - - - - - - - - - - - - -
Suministro electrico 60 - - - - - x - - - - - - - -
Suministro electrico 60 - - - - - x - - - - - - - -
Suministro electrico 60 - - - - - x - - - - - - - -
Suministro electrico 60 - - - - - x - - - - - - - -
- - - - - - - - - - - - -
Suministro electrico 60 - - - - - - - - - - - - - -
- - - - - x - - - - - - - -
Suministro electrico 60 - - - - - x - - - - - - - -
Suministro electrico 60 - - - - - - - - - - - - - -
Temperature Signal
-
-
-
-
-
-
-
-
-
-
-
Cable (Wall)
-
-
-
-
-
-
-
-
-
-
-
Ethernet - VLAN
- -
- -
- -
- -
- -
- -